RxDoctor Payments Data

Eric Costanzo, DO

Pulmonary Disease · Manasquan, NJNPI 1700977923

Payments from drug & device makers

$3,882in general payments, 2019–2025

Across 215 payments — averaging $18.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Philips North America LLC$719
  • AstraZeneca$600
  • Ambu Inc.$555
  • GSK$338
  • Boehringer Ingelheim$313
  • Regeneron Healthcare Solutions, Inc.$181
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$3,79198%
  • Education$912%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,882 in reported general payments places this provider in the 60th percentile of 472 pulmonary disease providers in New Jersey.

See all pulmonary disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$224,234
Medicare patients
822
Services billed
1,918

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tyvaso DpiTreprostinil20$450,784
OpsumitMacitentan25$307,987
OfevNintedanib Esylate13$171,003
Trelegy ElliptaFluticasone/Umeclidin/Vilanter79$71,505
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr35$22,570
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$6,962
Albuterol Sulfate HfaAlbuterol Sulfate58$2,302
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate13$1,938
Roflumilast13$1,857
Montelukast Sodium24$211
Prednisone49$138
Methylprednisolone18$102
Azithromycin29$74
Furosemide11$21

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit$80$307,98725 claims
Boehringer IngelheimOfev$313$171,00313 claims
GSKTrelegy Ellipta, Anoro Ellipta$338$94,075114 claims
AstraZenecaBreztri Aerosphere$600$6,96212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 472 pulmonary disease providers in New Jersey.

Other pulmonary disease in Manasquan

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →